This move is archived. Current quotes and coverage live on the stock page.
Follow TGTX
TG Therapeutics Inc (TGTX) is experiencing a notable uptick in its stock price, reflecting growing investor confidence.
TG Therapeutics Inc (NASDAQ:TGTX) is rising today, driven by a combination of positive market sentiment and strong fundamentals. The stock saw an increase of 2.27%, closing at CA$58.16, as investors responded to recent developments and optimistic projections regarding its flagship product.
TG Therapeutics Inc
TGTX.US
TGTX.US
TG Therapeutics Inc
WealthAwesomeMarket cap
$9.16B
P/E
21.8x
52W high
$63.60
52W low
$26.76
1W change
-2.21%
Beta
1.81
Analyst Price Targets
Based on 8 analysts covering TGTX · as of Oct 5, 2026
Wall Street analysts forecast TGTX stock price to rise 16.5% over the next 12 months.
Consensus
Strong Buy4.50 / 5.00
Avg. Target
C$69.71
+16.5% Upside
Current Price
C$59.83
Last close
Analyst Breakdown (8 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TGTX's historical volatility
30-Day Vol
40.4%
Annualized
90-Day Vol
44.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$71.52
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$63.49 | C$55.24 – C$72.98 |
| 60 trading days | C$67.39 | C$55.34 – C$82.06 |
| 90 trading days | C$71.52 | C$56.19 – C$91.04 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: With TG Therapeutics trading at a valuation perceived as undervalued by analysts, investors may find it an attractive opportunity, especially with the upcoming launch of BRIUMVI.
2.27% Increase in Stock Price
TG Therapeutics has shown a robust 30-day share price return of 12.36% and a year-to-date return of 92.86%, indicating strong momentum.
Bull case
Analysts believe the stock is about 19% undervalued compared to its fair value of $69.71, suggesting there’s room for growth. The planned launch of subcutaneous BRIUMVI could expand its market reach and meet the increasing demand for advanced therapeutics.
Bear case
Despite the positive outlook, TG Therapeutics faces challenges. The company relies heavily on BRIUMVI, and increasing competition could affect pricing and market share. Any setbacks in product performance might negatively impact investor sentiment.
Market Performance and Analyst Sentiment
TG Therapeutics has gained attention as it approaches its H.C. Wainwright conference appearance. The stock's recent bounce off its 50-day moving average has attracted investors, particularly given its impressive performance metrics. Analysts suggest that the stock is currently undervalued, with a fair value estimate of $69.71, indicating a potential upside for investors.
Upcoming Catalysts and Growth Potential
The anticipated launch of subcutaneous BRIUMVI is a significant catalyst for TG Therapeutics. This product could capture a substantial share of the anti-CD20 multiple sclerosis market, increasing the company's revenue potential. As demographic trends favor rising demand for chronic disease treatments, TG Therapeutics is well-positioned for continued growth.
Risks and Considerations
While the outlook for TG Therapeutics appears promising, investors should remain cautious. The company's heavy reliance on BRIUMVI and the competitive landscape could pose challenges. Monitoring these factors will be crucial for assessing the stock's future performance.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
